» Articles » PMID: 31660895

Combined Quantitation of HMGA2 MRNA, MicroRNAs, and Mitochondrial-DNA Content Enables the Identification and Typing of Thyroid Tumors in Fine-needle Aspiration Smears

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2019 Oct 30
PMID 31660895
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Analysis of molecular markers in addition to cytological analysis of fine-needle aspiration (FNA) samples is a promising way to improve the preoperative diagnosis of thyroid nodules. Nonetheless, in clinical practice, applications of existing diagnostic solutions based on the detection of somatic mutations or analysis of gene expression are limited by their high cost and difficulties with clinical interpretation. The aim of our work was to develop an algorithm for the differential diagnosis of thyroid nodules on the basis of a small set of molecular markers analyzed by real-time PCR.

Methods: A total of 494 preoperative FNA samples of thyroid goiters and tumors from 232 patients with known histological reports were analyzed: goiter, 105 samples (50 patients); follicular adenoma, 101 (48); follicular carcinoma, 43 (28); Hürthle cell carcinoma, 25 (11); papillary carcinoma, 121 (56); follicular variant of papillary carcinoma, 80 (32); and medullary carcinoma, 19 (12). Total nucleic acids extracted from dried FNA smears were analyzed for five somatic point mutations and two translocations typical of thyroid tumors as well as for relative concentrations of HMGA2 mRNA and 13 microRNAs and the ratio of mitochondrial to nuclear DNA by real-time PCR. A decision tree-based algorithm was built to discriminate benign and malignant tumors and to type the thyroid cancer. Leave-p-out cross-validation with five partitions was performed to estimate prediction quality. A comparison of two independent samples by quantitative traits was carried out via the Mann-Whitney U test.

Results: A minimum set of markers was selected (levels of HMGA2 mRNA and miR-375, - 221, and -146b in combination with the mitochondrial-to-nuclear DNA ratio) and yielded highly accurate discrimination (sensitivity = 0.97; positive predictive value = 0.98) between goiters with benign tumors and malignant tumors and accurate typing of papillary, medullary, and Hürthle cell carcinomas. The results support an alternative classification of follicular tumors, which differs from the histological one.

Conclusions: The study shows the feasibility of the preoperative differential diagnosis of thyroid nodules using a panel of several molecular markers by a simple PCR-based method. Combining markers of different types increases the accuracy of classification.

Citing Articles

HMGA2 Overexpression in Papillary Thyroid Cancer Promotes Thyroid Cell Dedifferentiation and Invasion, and These Effects Are Counteracted by Suramin.

Van Branteghem C, Henry N, Craciun L, Maenhaut C Int J Mol Sci. 2025; 26(4).

PMID: 40004107 PMC: 11854921. DOI: 10.3390/ijms26041643.


Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.

Veryaskina Y, Titov S, Skvortsova N, Kovynev I, Antonenko O, Demakov S Int J Mol Sci. 2025; 25(24.

PMID: 39769169 PMC: 11679576. DOI: 10.3390/ijms252413404.


Could Be a Promising Marker for Preoperative Diagnosis of High-Grade Papillary Thyroid Carcinoma?.

Titov S, Kozorezova E, Lukyanov S, Sergiyko S, Demenkov P, Veryaskina Y Diagnostics (Basel). 2024; 14(23).

PMID: 39682560 PMC: 11640196. DOI: 10.3390/diagnostics14232652.


BRAF Mutation Analysis in Fine-Needle Aspiration Cytology of Fixed Slide Specimens in Patients with Papillary Thyroid Carcinoma.

Cheraghi S, Honardoost M, Abdolmaleki F, Khamseh M Med J Islam Repub Iran. 2024; 38:83.

PMID: 39678775 PMC: 11644031. DOI: 10.47176/mjiri.38.83.


Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing.

Lukyanov S, Titov S, Kozorezova E, Demenkov P, Veryaskina Y, Korotovskii D Int J Mol Sci. 2024; 25(13).

PMID: 39000197 PMC: 11241318. DOI: 10.3390/ijms25137090.


References
1.
Yoo S, Lee S, Kim S, Jee H, Kim B, Cho H . Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers. PLoS Genet. 2016; 12(8):e1006239. PMC: 4975456. DOI: 10.1371/journal.pgen.1006239. View

2.
Stokowy T, Wojtas B, Krajewska J, Stobiecka E, Dralle H, Musholt T . A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas. Mol Cell Endocrinol. 2014; 399:43-9. DOI: 10.1016/j.mce.2014.09.017. View

3.
Swierniak M, Wojcicka A, Czetwertynska M, Stachlewska E, Maciag M, Wiechno W . In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013; 98(8):E1401-9. PMC: 5399477. DOI: 10.1210/jc.2013-1214. View

4.
. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

5.
Jin L, Seys A, Zhang S, Erickson-Johnson M, Roth C, Evers B . Diagnostic utility of IMP3 expression in thyroid neoplasms: a quantitative RT-PCR study. Diagn Mol Pathol. 2010; 19(2):63-9. DOI: 10.1097/PDM.0b013e3181b6a528. View